Sánchez-Paniagua López, MartaGonzález Burgos, Elena MaríaIglesias Peinado, IreneLozano Fernández, RafaelGómez-Serranillos Cuadrado, María Pilar2023-06-172023-06-172020-04-132218-273X10.3390/biom10040603https://hdl.handle.net/20.500.14352/8311Tea made from Camellia sinensis leaves is one of the most consumed beverages worldwide. This systematic review aims to update Camellia sinensis pharmacological activity on metabolic and endocrine disorders. Inclusion criteria were preclinical and clinical studies of tea extracts and isolated compounds on osteoporosis, hypertension, diabetes, metabolic syndrome, hypercholesterolemia, and obesity written in English between 2014 and 2019 and published in Pubmed, Science Direct, and Scopus. From a total of 1384 studies, 80 reports met inclusion criteria. Most papers were published in 2015 (29.3%) and 2017 (20.6%), conducted in China (28.75%), US (12.5%), and South Korea (10%) and carried out with extracts (67.5%, especially green tea) and isolated compounds (41.25%, especially epigallocatechin gallate). Most pharmacological studies were in vitro and in vivo studies focused on diabetes and obesity. Clinical trials, although they have demonstrated promising results, are very limited. Future research should be aimed at providing more clinical evidence on less studied pathologies such as osteoporosis, hypertension, and metabolic syndrome. Given the close relationship among all endocrine disorders, it would be of interest to find a standard dose of tea or their bioactive constituents that would be beneficial for all of them.engAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttps://doi.org/10.3390/biom10040603https://www.mdpi.com/2218-273X/10/4/603open accessCamellia sinensismetabolic disordersendocrine disordersteaAnálisis clínicosFarmacología (Farmacia)Química farmaceútica3209 Farmacología2390 Química Farmacéutica